Get started
Author

Pan Wu

OpenAlex ID: A5032018290
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study
2022 · Marcus A. Mall, Rossa Brugha, et al. · American Journal of Respiratory and Critical Care Medicine · 159
Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR : A Phase 2 Placebo-controlled Clinical Trial
2023 · Mirjam Stahl, Jobst Roehmel, et al. · Annals of the American Thoracic Society · 30
Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial
2026 · Charles L Daley, Jakko van Ingen, et al. · Annals of the American Thoracic Society · 7
Amikacin Liposome Inhalation Suspension in Newly Diagnosed Mycobacterium avium Complex Lung Disease: A Phase 3b, Double-blind, Randomized Clinical Trial (ENCORE)
2026 · Charles L Daley, Kozo Morimoto, et al. · American Journal of Respiratory and Critical Care Medicine
PDF
Late Breaking Abstract - Microbiologic outcomes and recurrence in patients with newly diagnosed Mycobacterium avium complex lung disease (MACLD) in the phase 3b ENCORE trial
2026 · Jakko van Ingen, Eva Van Braeckel, et al. · European Respiratory Journal
Works count: 5
Citation count: 196
H-index: 3
I10-index: 2
Year
Topic
Type